Table 1.

Patient characteristics.

Patient characteristicsN = 75
Age - Median (Range) years63 (23–79)
Male sex, no. (%)50 (67)
Histology, no. (%)
De novo DLBCL50 (67)
Transformed indolent lymphoma25 (33)
Bulky disease ≥10 cm, no. (%)12 (16)
Ann Arbor stage III/IV, no. (%)62 (83)
IPI ≥ 3 at apheresis, no. (%)51 (69)
Lines of therapy ≥3, no. (%)46 (61)
Bridging therapy, no. (%)48 (64)
 Chemotherapy26 (54)
 Radiation ± chemotherapy10 (21)
 Steroids only11 (23)
 Other6 (12.5)
Prior autologous HSCT, no. (%)11 (19)
Not eligible for ZUMA-1, no. (%)36 (48)
 Renal insufficiency6 (17)
 VTE within 6 months5 (14)
 Thrombocytopenia5 (14)
 Symptomatic effusion3 (8)
 Other17 (47)
  • Abbreviations: HSCT, hematopoietic stem cell transplantation; IPI, international prognostic index; VTE, venous thromboembolism.